Paracrine release of ovine interferon tau (oIFNT) from the conceptus alters release of endometrial prostaglandin F2 alpha (PGF) and prevents luteolysis.
INTRODUCTION
The corpus luteum (CL) produces progesterone, which is essential for establishment and maintenance of pregnancy and regulation of estrous cycles in mammals [1] [2] [3] . The CL is composed of two types of steroidogenic cells called large and small luteal cells [4] . Large luteal cells are steroidogenic because of constitutively active protein kinase A (PKA) [5] and, consequently, secrete approximately 7-fold more progesterone in an unstimulated state than small luteal cells [6] . Small luteal cells contain luteinizing hormone (LH) receptors and produce progesterone in response to stimulation by LH. In ruminants, endometrial-derived prostaglandin F2 alpha (PGF) initiates luteolysis [1] , which triggers intraluteal production of PGF to complete structural regression of the CL [7] .
Because ligation of the gravid horn protects the CL ipsilateral to the conceptus, while the contralateral CL regresses, Moor and Rowson [8] and Mapletoft et al. [9] concluded that the conceptus has a local effect in maintaining the CL during early pregnancy. These studies were interpreted to suggest that there was no systemic mediator that rescued the CL during early pregnancy. However, these findings do not exclude the possible endocrine action of conceptus-derived factors on the CL in the context of resistance to PGF and longer-term survival of the CL during pregnancy [10, 11] . In fact, several studies have indicated that the CL during pregnancy is more resistant to lytic effects of PGF [10, [12] [13] [14] . Exactly why and how this luteal resistance to PGF occurs during pregnancy is a focus of the present studies.
Maternal recognition of pregnancy in ruminants requires secretion of interferon-tau (IFNT) by the trophectoderm [15] during the peri-implantation period of pregnancy, which prevents return to estrus [16] . IFNT acts in a paracrine manner to silence expression of estrogen receptor alpha (ESR1) and, consequently, oxytocin receptor (OXTR) in endometrial luminal epithelium and superficial glandular epithelium, thereby altering release of luteolytic pulses of PGF [17] . IFNT also stimulates many genes (interferon-stimulated genes [ISGs] ) in the uterine glandular epithelium and stromal cells [18] [19] [20] and in peripheral tissues such as the CL and liver [21, 22] .
ISG15, also called ubiquitin cross-reactive protein because of its cross-reactivity with anti-ubiquitin antibody [23] , is upregulated in the mouse [24] , human [25] , and ruminant [26] endometrium. ISG15 is induced in response to type I IFN, such as IFNT, and becomes conjugated to intracellular proteins [27] in a mechanism similar, but not identical, to ubiquitin [28] . ISG15 mRNA and protein are up-regulated in large luteal cells from Day 15 pregnant compared to nonpregnant sheep [22] . Also, bioactive type I IFN is detected in serum from the uterine vein of pregnant sheep on Day 15 of pregnancy using an antiviral assay [22] . Preadsorption of uterine vein serum samples from Day 15 of pregnancy with anti-IFNT antibody blocks this antiviral activity [21] . Finally, IFNT is present in uterine vein blood on Day 15 of pregnancy, based on a highly sensitive radioimmunoassay and mass spectroscopy approach (Antoniazzi and Hansen, unpublished data). These results are interpreted to mean that IFNT is the type I IFN present in uterine vein serum, is responsible for the antiviral activity in uterine vein blood on Day 15 of pregnancy [21] , and acts in endocrine action on the CL to induce ISGs.
Because IFNT appeared to be released into the uterine vein during early pregnancy, a new model to study the endocrine action of IFNT was developed [21] . Continuous infusion of IFNT into the uterine vein using an osmotic pump resulted in an induction of ISG15 in the CL and was chosen as a model for study of the endocrine action of IFNT. Osmotic pump delivery of recombinant ovine IFNT (roIFNT; 200 lg/day) into the uterine vein for 7 days starting on Day 10 of the estrous cycle blocked the luteolytic action of endogenous PGF and extended estrous cycles beyond 32 days [21] . In addition, 24-h infusion of roIFNT (200 lg/day) into the uterine vein starting on Day 10 of the estrous cycle provided partial protection of the CL as determined by maintenance of serum progesterone concentrations following challenge with exogenous PGF on Day 10.5 [4] .
Because 12-h pre-exposure to roIFNT provided partial protection to the CL from an exogenous challenge with PGF, we hypothesized that this induction of luteal resistance to PGF would be further potentiated following 24-h endocrine exposure to roIFNT. Infusion of roIFNT into the uterine vein or jugular vein for 72 h, with exogenous PGF challenge at 24 h after insertion of the pumps, was performed in the present studies so that release of progesterone and induction of genes in the CL that might contribute to resistance to lytic actions of PGF could be more extensively examined. Osmotic pump delivery of roIFNT into the jugular vein also was completed to determine if systemic delivery of roIFNT provided protection against luteolysis.
PGF binds Gq coupled receptor (PTGFR) to activate apoptosis and destabilize CL viability [29] . PGE2 is luteotrophic and binds several receptors, one of which is PTGER4 [30, 31] . These PGs can be transported across membranes via the transporter, SLCO2A1 [32] . It was reasoned that IFNT might down-regulate PTGRFR, while stabilizing the abundance of SLCO2A1 and PTGER4. It also was reasoned that because PGF induces luteal regression through induction of apoptosis, IFNT might counter this lytic action by stabilizing cell survival genes. The hypothesis that intracellular pathways associated with viability of the CL were stabilized in response to infusion with IFNT was tested herein. Three cell-survival genes were examined. Bcl-xL, a member of Bcl-2 protein family, is known to inhibit Bax-induced caspase activation and apoptosis [33] by blocking the cell death pathway upstream of caspase activity [34] . The serine/threonine kinase AKT, also known as protein kinase B (PKB), has several roles in cell survival and growth [35] , consequently preventing apoptosis. X-linked inhibitor of apoptosis protein (XIAP), a member of intracellular antiapoptotic proteins, is characterized by the presence of a caspase recruitment domain [36] , which is a direct inhibitor of caspase-3 [37] and caspase-7 [36] , and regulates AKT activity in human ovarian epithelial cancer cells [38] .
Osmotic pumps delivering different quantities of roIFNT into the jugular or uterine vein for 72 h were used to test the hypothesis that IFNT acts directly on the CL to protect against luteolysis during maternal recognition and establishment of early pregnancy in ruminants. Finally, different concentrations of roIFNT were examined for efficacy in inducing ISGs, stabilizing cell survival genes, and inhibiting luteolytic mechanisms using both in vivo (osmotic pumps and different methods of delivery) and in vitro (isolated and cultured small, large, and mixed luteal cells) approaches.
MATERIALS AND METHODS

Animals and Experimental Design
All experimental procedures were approved by the Colorado State University Animal Care and Use Committee. Mature Western Range Whiteface ewes were from local sheep producers and were treated during the luteal phase of the estrous cycle with two injections of Lutalyse (5 mg, i.m.; Pfizer, New York, NY) 4 h apart to synchronize estrus (Day 0), which was confirmed by using a caudoepididectomized ram.
Validation of Osmotic Pump Infusion of roIFNT into Uterine Vein for 24 h
Release of IFNT into the uterine vein on Day 15 of pregnancy was estimated to be ;200 lg/day based on antiviral activity in serum [22] . Total blood volume was estimated to be 3.48 L based on an average body weight of 60 kg and blood volume of 58 ml/kg for ewes. Thus, osmotic pumps were loaded to deliver 200 lg/d or 8.3 lg/h of IFNT into the uterine vein. Considering the blood volume described above, systemic levels of roIFNT in circulation were estimated at around 2.4 ng/ml/h. This is a biologically relevant concentration in the context of a dissociation constant (Kd) of 3.7 3 10 À10 M [39] and estimated 50% occupancy of the receptors at 6.3 ng IFNT/ml.
Previously, we surgically installed osmotic pumps (model #2001D; Durect Corporation, Cupertino, CA) delivering 200 lg/day of bovine serum albumin (BSA) or roIFNT (n ¼ 12 per group) into the uterine vein on Day 10 of the estrous cycle for 24 h [21] (Fig. 1A) . After 12-h exposure to either BSA or roIFNT, PGF (0 or 4 mg/58 kg body weight) was administered (n ¼ 6 ewes in each group) to induce early lytic responses in the CL. CL were collected 12 h later. The 4 mg/58 kg body weight dose of PGF has been used by our group [21] because it causes luteolysis during the estrous cycle, but not during maternal recognition of pregnancy [10] . All ewes were euthanized 24 h after surgery, and CL, endometrium, and uterine vein blood were collected as previously described [21, 22] . Infusion of 200 lg roIFNT/day into the uterine vein on Day 10 partially protected the CL from the lytic actions of injected PGF on Day 10.5 [21] . Endometrium and CL collected in a previous experiment by Bott et al. [21] were further examined in the present studies.
Osmotic Pump Infusion of 20 or 200 lg roIFNT/Day into the Uterine Vein for 72 h
Osmotic pumps with 72-h delivery (model #1003D; Durect Corporation) were loaded with 600 lg BSA or roIFNT to deliver 200 lg/day into the uterine vein (n ¼ 5 per group) and were installed on Day 10 of the estrous cycle (Fig.  1A) . Six additional ewes underwent sham surgeries in which catheters were inserted into the uterine vein (with no pumps) as procedure controls. Pumps were attached to a 0.94-mm outer diameter catheter and surgically implanted as previously described [21] on Day 10 of the estrous cycle. Catheters from pumps ANTONIAZZI ET AL.
were inserted into the uterine vein in a position that was upstream of the ovarian plexus and ipsilateral to the CL. Pumps were anchored in place with cyanoacrylate glue. In ewes with one CL on each ovary, the CL was noted as being ipsilateral or contralateral to the side of the reproductive tract on which the pump was installed. Ewes from both BSA-and roIFNT-infused groups served as controls for those groups receiving PGF injection.
Pumps with 72-h delivery also were loaded with 60 lg roIFNT to deliver 20 lg/day into the uterine vein to determine if a 10-fold reduction in the amount of roIFNT also induced ISGs in the CL and provided protection against a challenge with PGF (n ¼ 5 ewes). Finally, 72-h pumps were loaded to deliver 200 lg roIFNT/day into the jugular vein to test the hypothesis that systemic delivery also protected the CL from a challenge with PGF (n ¼ 5 per group). The catheter from the pump was inserted into the jugular vein at the level of the third to fourth cervical vertebrae. The catheter and pump were anchored with cyanoacrylate glue in the s.c. space.
After 24-h exposure to either BSA or roIFNT, 4 mg PGF/58 kg body weight was injected (i.m.). Blood was collected three times per day for determination of concentrations of progesterone in serum. All ewes were euthanized 72 h after pump installation, and CL, endometrium, and uterine vein blood were collected as previously described [21, 22] .
Progesterone Radioimmunoassay
Serum concentrations of progesterone were determined by radioimmunoassay as previously described [40] . The sensitivity of the assay was 6.07 pg, and the intra-and interassay coefficients of variation were 12.07% and 7.13%, respectively.
Dose-Dependent Increase in ISG in Isolated Luteal Cells Cultured with roIFNT
Large and small luteal cells were isolated via elutriation as previously described [41] . Briefly, CLs were decapsulated, sliced, and dissociated into 
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single-cell suspensions with 0.25% collagenase and 0.05% deoxyribonuclease. Mixed luteal cells were obtained from the cell suspension before elutriation. Luteal cells were separated by centrifugal elutriation into small (l0-20 lm) and large (20-35 lm) cell fractions [41] . Isolated luteal cells were plated in 35-mm 6-well plates at 2 3 10 6 , 5 3 10 5 , and 1 3 10 6 for small, large, and mixed luteal cells, respectively, and cultured overnight in M-199 supplemented with 5% fetal bovine serum and 1% antibiotics (penicillin and streptomycin). The next morning, the medium was replaced with serum-free medium for 3 h followed by a treatment with 0, 0.1, 1, 10, and 100 ng/ml roIFNT for 24 h. Cells were washed with cold PBS, lysed directly in the culture plate by adding 1 milliliter per well of TRI reagent (Sigma Chemical Co., St. Louis, MO), and stored at À808C until isolation of total mRNA.
Total RNA Isolation and Semiquantitative Real-Time PCR Extraction of RNA from tissues (CL, liver, and endometrium; 100 mg) was performed using TRI reagent. After extraction, RNA was treated with DNase I and purified using RNeasy MinElute Cleanup Kit (both from Qiagen, Valencia, CA). Single-stranded cDNA was synthesized from 1 lg of total RNA using an iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA) according to the manufacturer's protocol. Reactions were performed using a final volume of 10 ll per well using iQ Supermix (Bio-Rad) with cDNA (2 ll) as a template. Amplification was performed at 958C for 30 sec, 628C for 30 sec, and 728C for 15 sec for 40 cycles. Target mRNA concentration was normalized to GAPDH mRNA concentration. The primer sequences (Supplemental Table S1 ; all Supplemental Data are available online at www.biolreprod.org) were designed to generate single-product melting curves and consistent amplification efficiencies. All amplicons were verified to encode respective mRNA targets by sequencing.
Western Blot Analysis
Proteins were extracted using a radio-immunoprecipitation assay lysis buffer with PMSF (Sigma), sodium metavanadate (Sigma), and benzamidine (Sigma). Sample protein concentrations were quantified using the BCA Pierce Protein Analysis Kit (Thermo Scientific, Rockford, IL). Protein (50 lg) was loaded in each lane and resolved on 12% SDS-PAGE gel followed by transfer to nitrocellulose membranes (Biotrace NT; Pall life Sciences, Pensacola, FL). Membranes were blocked overnight in 5% nonfat dry milk in Tris-buffered saline þ Tween 20 (TBST) at 48C. Samples were analyzed for ISG15 using a monoclonal antibody (5F10; 1:10 000) [42] followed by incubation with an anti-mouse secondary antibody (0.2 lg/ml; Santa Cruz Biotechnology Inc., Santa Cruz, CA). Protein samples were also analyzed for PTGFR (1 lg/ml) and SLCO2A1 (1 lg/ml) using a polyclonal antibody (Cayman Chemicals, Ann Arbor, MI) with an anti-rabbit secondary antibody (1:2000, 0.5 lg/ml; Promega, Madison, WI). Blots were incubated with primary antibodies for 1 h at room temperature. After three washes in TBST for 5 min, the membranes were incubated for 1 h at room temperature with their respective secondary antibody. The membranes were washed again three times for 5 min in TBST, and proteins were detected using the Amersham ECL Plus Western Blotting Detection Reagents (GE Healthcare, Piscataway, NJ). Quantification was performed with optical densitometry relative to beta-actin (Santa Cruz Biotechnology Inc.).
Immunohistochemical Analysis
CLs were fixed in 4% paraformaldehyde for 24 h, transferred to 70% ethanol, and then processed and paraffin embedded. Serial sections (5 lm) were mounted onto aminopropylsilane-coated glass microscope slides. Briefly, the sections were deparaffinized in clearing agent, rehydrated in a graded series of ethanol (100%, 95%, and 70%), and washed in distilled water. Antigen retrieval was accomplished by heating sections twice in a microwave oven for 5 min each in 10 mM sodium citrate buffer (pH 6.0). Next, endogenous peroxidase was inactivated by treatment with 3% H 2 O 2 in methanol for 15 min at room temperature. The slides were then washed in 0.1 M glycine in PBS (pH 7.4). After blocking with normal horse serum (2%) in 1% BSA solution for 1 h at room temperature, the sections were incubated with monoclonal antibody for ISG15 (5F10; 1:5000) [42] for 1 h at room temperature. As a negative control, sections were incubated with blocking solution instead of primary antibody. After the incubation, the sections were washed in TBS three times for 5 min each, and then primary antibodies were visualized with Vectastain Elite ABC kit (Vector Laboratories Inc., Burlingame, CA) per the manufacturer's recommendations. The binding sites were visualized with DAB (Sigma) in 1 ml of bi-distillated H 2 O. The slides were counterstained with hematoxylin for 3 min and washed for 5 min in tap water. The sections were dehydrated in a graded series of ethanol (75%, 95%, and 100%), cleared, and mounted.
Statistical Analysis
All statistical analyses were performed using the SAS software package (SAS Institute Inc., Cary, NC). Data are presented as mean 6 SEM, unless otherwise stated. P 0.05 was considered significant. Continuous data were analyzed by ANOVA using the General Linear Models followed by a protected t-test. GAPDH mRNA concentrations were analyzed among all groups and showed no difference, and thus were used to normalize each targeted mRNA amplification by using the DCT (target CT-GAPDH CT) values [43, 44] . Data were analyzed using target values normalized to GAPDH using DCT and represented by graphing 2
ÀDCT values calculated for each group. Some ewes had varying numbers of CL and consequently varying baseline concentrations of progesterone. For this reason, serum concentrations of progesterone were plotted as a percent change from the time of PGF challenge.
RESULTS
Study 1: 24-h Infusion of 200 lg roIFNT into the Uterine Vein
Recombinant oIFNT or BSA was infused at 200 lg/day into the uterine vein. Twelve hours following insertion of pumps, PGF was injected in one half of the ewes (n ¼ 6 per group), and then blood samples were collected every 2 h for an additional 12 h to monitor concentrations of progesterone in serum [21] . Concentrations of progesterone in serum of ewes infused with BSA or IFNT without PGF injection at 12 h did not change. However, injection with PGF caused a decline in concentrations of progesterone in serum in BSA-infused ewes within 6 h that remained low through 12 h following injection of PGF, reflecting luteal regression (see [21] ). Infusion of roIFNT for 12 h into the uterine vein partially protected the CL from challenge by PGF, as reflected in the concentrations of progesterone in serum that were intermediate and not different from control values (BSA and IFNT infusion alone) or those of the BSAþPGF ewes [21] .
In addition to providing protection of the CL against the lytic effects of exogenous PGF, the 24-h infusion of roIFNT induced ISG15, which immunolocalized to large and small luteal cells (Fig. 1B) . The localization of ISG15 in small and large luteal cells was induced by infusion of roIFNT but was not affected by treatment with exogenous PGF.
Study 2: 72-h Infusion of roIFNT
Osmotic pump infusion of controls (BSA or roIFNT without PGF challenge) into the uterine vein had no effect on concentrations of progesterone in serum over the 72-h blood sampling periods (Fig. 1) . Delivery of roIFNT into the uterine vein at 20 lg/day blocked the decline in concentrations of serum progesterone following PGF injection at 24 h that occurred in BSA-infused ewes injected with PGF at 24 h (Fig.  1) . Likewise, systemic delivery of 200 lg roIFNT/day into the jugular vein blocked the decline in serum progesterone following injection of PGF at 24 h that occurred in BSAinfused ewes (Fig. 1) .
Increase in Luteal ISG15 Following Infusion of roIFNT
An increase in concentration of ISG15 mRNA in the CL occurred when ewes were infused with 20 or 200 lg/day of roIFNT into the uterine vein ( Fig. 2A) . Infusion of roIFNT at 20 (not shown) and 200 lg/day (Fig. 2B) induced increase in ISG15 mRNA concentrations in the CL ipsilateral and contralateral to the uterine vein in which the catheter from the osmotic pump was inserted. Likewise, ISG15 mRNA concentrations increased in liver and endometrium in response to infusion of 200 lg/day of roIFNT into the uterine vein (Fig.  2B) . The greatest concentration of ISG15 mRNA was in the ANTONIAZZI ET AL.
liver, while the lowest concentration was in the endometrium following infusion with roIFNT (Fig. 2B) .
Endometrial ESR1 mRNA Concentrations Are Suppressed Following 72 h, but Not 24 h, of roIFNT Infusion into the Uterine Vein Endometrial concentrations of ESR1 mRNA did not differ in ewes infused with BSA into the uterine vein that were injected or not injected with PGF; therefore, these values were pooled across PGF treatment to represent the BSA-infused group. PGF treatment also had no effect on endometrial ESR1 mRNA concentrations in ewes infused with roIFNT for 24 h; therefore, these data were pooled to represent the roIFNT-infused group. Note that the 24-h infusion time represents Days 10-11 of the estrous cycle, which is a time during which ESR1 mRNA concentrations would not be expected to change or be upregulated. ESR1 mRNA abundance was not different in endometrium from ewes infused with BSA compared to those infused with roIFNT at 24 h (Fig. 2C) . However, 72-h infusion of 200 lg roIFNT/day into the uterine vein decreased ESR1 mRNA concentrations in endometrium compared to BSAinfused ewes (Fig. 2D) . The 72-h infusion time represents Days 10-13 of the estrous cycle, which is just prior to the expected increase in ESR1 and OXTR mRNAs. Very low concentrations of OXTR mRNA did not differ for BSA compared to roIFNT after 72-h infusion into the uterine vein starting on Day 10 of the estrous cycle (Supplemental Fig. S1 ), which may not be surprising considering the stage of the estrous cycle during which these samples were collected.
Concentrations of mRNA for ESR1, OXTR, SLCO2A1, and Prostaglandin Receptors in the CL Following 24-or 72-h Infusion of roIFNT into the Uterine Vein
The mRNAs encoding ESR1, OXTR, SLCO2A1, PTGFR, PTGER2, PTGER3, and PTGER4 were examined in the CL after 24-or 72-h infusion of BSA or roIFNT (Fig. 3, A-F) . 
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After 24 and 72 h of either BSA or roIFNT infusion, concentrations of ESR1, OXTR, PTGER2, and PTGER3 mRNAs did not differ in the CL between treatment groups (not shown). However, SLCO2A1 mRNA decreased (P , 0.001) following exogenous PGF regardless of roIFNT treatment (Fig. 3A) . This decrease in concentration of SLCO2A1 mRNA in response to PGF also occurred following 72-h infusion of BSA. The lack of a protective effect of roIFNT on down-regulation of SLCO2A1 mRNA in response to exogenous PGF was confirmed following the 72-h infusion of 20 lg/day into the uterine vein as well as 200 lg/day into the jugular vein (Fig. 3B) .
Concentrations of PTGFR mRNA decreased (P , 0.001) in response to PGF following the 24-h infusion of BSA. PTGFR mRNA concentrations also decreased following 24-h infusion of roIFNT (Fig. 3C) . However, following infusion of BSA for 
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72 h, with PGF injection at 24 h, there was no impact on PTGFR mRNA. The lower dose of roIFNT, 20 lg/ml, had no effect on PTGFR mRNA by 72 h, whereas the 200 lg/day dose decreased concentrations of PTGFR mRNA (Fig. 3D) .
Infusion of roIFNT for 24 h increased concentrations of luteal PTGER4 mRNA, which were not affected by injection of PGF at 12 h (Fig. 3E) . However, infusion of roIFNT for 72 h had no impact on luteal PTGER4 mRNA regardless of concentration. Treatment with PGF alone for 72 h increased PTGER4 mRNA in the CL (Fig. 3F) .
PTGFR and SLCO2A1 Proteins in CL from Ewes Infused with roIFNT into the Uterine Vein for 24 h
PTGFR mRNA concentrations decreased in response to infusion of roIFNT into the uterine vein. SLCO2A1 mRNA concentrations decreased in response to PGF, which was not affected by infusion of IFNT. For these reasons, PTGFR and SLCO2A1 proteins were examined in the CL using Western blot analysis. Neither PTGFR nor SLCO2A1 differed in abundance in total CL protein extracts between the treatment groups.
Expression of Cell Survival Genes in the CL Following 24 or 72 h of roIFNT Infusion into the Uterine Vein
In BSA-infused ewes, PGF caused an acute decrease in CL concentrations of Bcl-xL mRNA (Fig. 4A) . This downregulation by PGF was partially attenuated when ewes were infused for 24 h with roIFNT. By 72 h, PGF had no effect on Bcl-xL mRNA concentrations in BSA-infused ewes or ewes infused with 20 lg roIFNT/day (Fig. 4B) . However, the 200 lg/day roIFNT treatment increased Bcl-xL mRNA, but not enough to block the slight attenuation caused by PGF.
AKT mRNA decreased in response to PGF following 24-h infusion of BSA (Fig. 4C) . This down-regulation of AKT mRNA by PGF was effectively blocked by infusion of roIFNT. By 72 h, the inhibitory action of PGF on AKT mRNA was not apparent, and only 200 lg/day roIFNT caused a slight increase, which was attenuated by the injection of PGF (Fig. 4D) .
XIAP mRNA decreased in response to PGF following 24-h infusion of BSA (Fig. 4E) . Infusion of roIFNT for 24 h increased XIAP mRNA and attenuated the decline caused by PGF to a level that was not different from BSA-infused controls. By 72 h, there was no impact of PGF on XIAP mRNA in the CL of BSA-infused ewes (Fig. 4F) . Also, at 72 h, both 20 and 200 lg/day doses of roIFNT increased XIAP mRNA concentration. Treatment with PGF blocked the increase in XIAP mRNA following 72-h infusion of 20 lg roIFNT/day, but only attenuated the increase caused by infusion of 200 lg roIFNT/day.
Study 3: Luteal Cell Culture-roIFNT Dose Response
Small, large, and mixed luteal cells had no detectable expression of ISG15 mRNA following 24-h culture with 0 ng roIFNT/ml. Small luteal cells responded to culture with 0.1 ng roIFNT/ml by up-regulating ISG15 mRNA, which increased further with 10 ng/ml roIFNT and reached a plateau at 100 ng/ ml roIFNT. Large luteal cells also had increased ISG15 mRNA concentrations when treated with 0.1 ng roIFNT/ml compared to controls, but there was no increase in concentrations at higher doses of roIFNT. Mixed luteal cells displayed a similar pattern of increase in ISG15 mRNA in response to roIFNT (Fig. 5) . Culture with 1 ng roIFNT/ml represented the lowest concentration of roIFNT that was associated with maximal ISG response.
DISCUSSION
Paracrine actions of IFNT on the endometrium have been extensively examined and found to entail induction of ISGs [18, 45, 46] , inhibition of up-regulation of ESR1, and, consequently, OXTR as well as pulsatile release of PGF (reviewed in [47] ). ISG15 is induced in bovine [42, 45] and ovine [46] endometria during early pregnancy. ISGs have been found to be induced in deep myometrial layers of the endometrium [48] as well as in ovine [49] and bovine [50] peripheral blood mononuclear cells, prompting the hypothesis that a mediator of IFNT action (e.g., an ''interferonomedin'' [51] ) or IFNT itself may be released into the uterine vein. We have learned that IFNT is released (Day 15 of pregnancy) into the uterine vein and induces the expression of ISGs in peripheral tissues, such as the CL and the liver [21, 22] . Within the CL, ISG15 is localized to some degree in small luteal cells, but is mostly localized to large luteal cells on Day 15 of pregnancy, and its expression can be induced in vitro by treatment with roIFNT [22] . We have verified that IFNAR1 and IFNAR2 mRNAs are present in the CL (data not shown), although concentrations do not appear to be altered to any significant extent by infusion of roIFNT.
In the first set of experiments using endocrine delivery of roIFNT [21] , delivery of 200 lg roIFNT/day into the uterine vein at a site upstream of the utero-ovarian vasculature beginning on Day 10 of the estrous cycle for a period of 24 h or 7 days was shown to induce ISG15 in the CL, liver, and endometrium within 24 h. In the model using 7-day roIFNT uterine vein infusion, the estrous cycles were extended beyond 32 days. This result is significant considering the very low levels of roIFNT infused [21] and when compared to previous studies [52] . For example, it is estimated that 200 lg/day (8.3 lg/h) roIFNT delivered into the uterine vein would produce systemic plasma concentrations of about 2.4 ng/ml. Other studies delivering IFN systemically used such high amounts (micrograms and milligrams) that hyperthermia was induced (discussed in [52] ). Also, attempts to increase fertility with IFNT in sheep actually caused high embryo mortality in ewes receiving amounts greater than 2 3 10 7 antiviral units/day [52] . Intrauterine infusion of roIFNT suppressed endometrial ESR1 and OXTR, whereas s.c. administration had no effect [52] . Both intrauterine and s.c. injection of roIFNT increased expression of ISGs, myxovirus resistance factor 1, and ISG15 in the CL [52] . Administration (i.m.) of 200 lg/day of roIFNT did not influence CL life span. However, a higher dose (2 mg/day, i.m.) extended the estrous cycle slightly to 22 days [53] . In the present experiments, we used much lower concentrations of roIFNT that were delivered at either 8.3 lg/h or 0.83 lg/h (200 or 20 lg/d).
CLs ispilateral or contralateral to the uterine vein into which roIFNT was infused were examined to test the hypothesis that IFNT might be leaving the uterus through a countercurrent exchange from the uterine vein to the ovarian artery in the plexus. To our knowledge, molecules the size of IFNT have not been reported to be exchanged in this plexus. Rather than inducing ISG15 mRNA and protein preferentially in the CL ispilateral to uterine vein infusion, roIFNT induced similar expression of ISG15 mRNA in the contralateral CL. Endocrine delivery of these concentrations of roIFNT into the uterine vein resulted in up-regulation of ISG15 mRNA in the liver, further suggesting systemic release and an endocrine action for IFNT. The magnitude of the ISG15 mRNA response in the IFNT PROTECTS THE CORPUS LUTEUM endometrium was significantly lower, probably because of lower blood flow in the endometrium (6.8 to 13.3 ml/min) [54] , and, consequently, less roIFNT being delivered to this tissue when compared to the liver (1850 to 5920 ml/min) [55] . However, even with blood flow in the CL estimated to be 7 to 8 ml/min [56] , luteal cells express similar levels of ISG15 mRNA as in the liver.
We investigated concentrations of endometrial ESR1 mRNA on Day 10 of the estrous cycle and found them to be similar at 24 h, but decreased following 72 h of roIFNT infusion into the uterine vein. There was no corresponding change in OXTR mRNA concentration during this period. Low concentrations and lack of up-regulation of ESR1 and OXTR mRNA would be expected, because Day 10-13 is prior to the induction of PGF pulses during the estrous cycle. These results are interpreted to mean that infusion of roIFNT into the uterine vein on Day 10 of the estrous cycle acts directly on the CL to prevent luteolysis. This endocrine mechanism, in addition to the wellcharacterized paracrine action of IFNT via type I IFN receptors on uterine luminal and superficial glandular epithelia to silence up-regulation of ESR1 and, consequently, OXTR transcription [57, 58] , contribute to sustained production of progesterone and uterine support of the conceptus.
The results of this study corroborated previous findings [21] that infusion of roIFNT into the uterine vein induced ISG15 in the CL both ipsilateral and contralateral to the pump. To confirm this finding, osmotic pumps were implanted to deliver roIFNT s.c. into the jugular vein, which resulted in a similar induction of ISG15 mRNA in both the ipsilateral and contralateral CL. To evaluate whether the systemic induction of ISG15 may be due to administration of supra-physiologic levels of roIFNT, which were consequently saturating or overloading IFNT receptors and the ability of these tissues to respond, osmotic pumps were loaded to deliver 10-fold lower concentrations, or 20 lg/day of roIFNT, into the uterine vein. Examination of ISG15 mRNA concentrations in both ipsilateral and contralateral CL revealed a similar magnitude of upregulation compared to infusion of the high dose (200 lg/day) of IFNT. Thus, regardless of dose (200 or 20 lg/day) or anatomic location of infusion (jugular or uterine veins), roIFNT induces ISG15 mRNA concentrations at similar levels in both the ispilateral and contralateral CL.
In a previous study [21] , concentrations of progesterone in serum were not affected following 24 h of BSA or roIFNT infusion into the uterine vein. PGF injection 12 h after initiating infusion of BSA caused a decline in serum concentrations of progesterone 6 h later, which never recovered to pre-PGF levels. Infusion of roIFNT did not prevent the initial decline in concentration of serum progesterone caused by injection of PGF. However, serum progesterone concentrations did recover in roIFNT-infused ewes after injection with PGF to levels similar to those for both BSA-and roIFNTinfused ewes not receiving PGF. Therefore, the hypothesis tested in the present study was that infusion of 200 lg/day of roIFNT into the jugular vein or 20 lg/day of roIFNT into the uterine vein for 72 h would protect the CL against the PGFinduced decline in serum progesterone. Concentrations of progesterone in serum did not change after infusing BSA or IFNT (200 or 20 lg/day) for 72 h into the uterine vein. PGF injection 24 h after BSA infusion into the uterine vein resulted in a 70%-80% decline in serum progesterone within the next 24 h, which was sustained through 48 h following PGF administration. However, serum progesterone did not change following PGF injection 24 h after infusion of 200 lg roIFNT/ day into the jugular or 20 lg/day into the uterine vein. These results clearly demonstrate that infusion of 200 lg/day of roIFNT into the jugular vein or 20 lg/day of roIFNT into the uterine vein for 72 h is sufficient to protect the CL from luteolytic effects of exogenous PGF. To our knowledge, these are the first studies to demonstrate that endocrine delivery of roIFNT provides luteal protection from exogenous treatment with PGF.
Luteal production of PGF may contribute to luteolysis in the ewe by amplifying the concentration of intraluteal PGF after being triggered by endometrial PGF. It has been shown that concentrations of PGDH and PTGS2 mRNAs in the CL increase on Day 13 of pregnancy when compared to the estrous cycle, suggesting that the CL of pregnancy is better able to degrade endogenous PGs resulting from increased PG biosynthesis due to up-regulation of PTGS2 [59] . Whether this increased synthesis of PGs through up-regulating PTGS2 resulted in preferential synthesis of PGE2 rather than PGF in the CL has not been examined until recently [21] . Previously, we reported that concentrations of mRNAs encoding proteins involved with the biosynthesis of PGs, such as PGDH, PTGES, PTGFS, and PTGS2, did not change following 24-h infusion of roIFNT into the uterine vein. These results suggest that IFNT does not induce luteal resistance through inhibiting mRNAs encoding intraluteal biosynthesis of PGs. Because these mRNAs remained unchanged 24 h following infusion of roIFNT, they were not examined further in the present studies following 72-h infusion. However, the possibility does exist that longer-term exposure of the CL to roIFNT might actually regulate this pathway.
PTGER2 is coupled to the cAMP signal transduction pathway and stimulates steroidogenesis and production of progesterone in cultured, luteinized human granulosa cells [60] . PTGER4 is also coupled via the G-protein receptor to cAMP (reviewed in [31] ), but to our knowledge, functional coupling to synthesis of progesterone has not been studied in the CL. PGE2 also has repressive effects on B cells and immune responses [61, 62] . In a more recent study [63] , PGE2 was shown to act through the PTGER4 to reduce in vivo proliferative properties in A20 B-lymphoma cells that overexpress PTGER4. This repression of proliferation by PGE2 was shown to involve attenuation of cell-cycle, energy-producing, and translational machinery through activation of PTGER4 and suppression of NFjB activation. In addition to potential luteotrophic actions, PGE2 may also contribute to terminal differentiation of luteal cells by suppressing their proliferation. Likewise, suppression of immune responses associated with luteal regression [64, 65] may contribute to luteal resistance and sustainability. In the present experiments, we report significant up-regulation of PTGER4 mRNA in the CL of ewes following 24-h infusion of roIFNT into the uterine vein. However, up-regulation of PTGER4 mRNA in the CL was not sustained at 72 h following uterine vein infusion of roIFNT; therefore, this response may represent an acute-early mechanism induced by IFNT. This may be the first description of an indirect luteotrophic and immunosuppressive role of IFNT in the CL, but further studies are necessary to examine these relationships.
Two obvious targets in the CL for development of resistance to luteolysis are PTGFR and SLCO2A1. Other groups have indicated that PTGFR mRNA [66] , protein [67] , and affinity IFNT PROTECTS THE CORPUS LUTEUM constant [67] are not attenuated during maternal recognition of pregnancy in sheep. Those studies concluded that the mechanism through which the ovine CL achieves resistance to PGF during early pregnancy does not involve PTGFR. We demonstrated suppression of PTGFR mRNA concentrations in the CL in response to 24-h and 72-h delivery of roIFNT into the uterine vein, but this is not supported by corresponding changes in protein. Likewise, SLC02A1 protein was not affected by infusion of roIFNT or injection with PGF. SLCO2A1 was examined in the present study because of its importance in ovine PG transport within the endometrium [32] and utero-ovarian plexus [68] and possible role in regulating release of PGF from large luteal cells during autocrine activation of PTGFR to induce luteolysis [69] . The changes in mRNA concentrations for these mediators of PGF action, without similar changes in protein based on Western blot, might be caused by luteal cell-specific changes, which may be clarified using immuonohistochemical approaches (our ongoing experiments).
Luteolysis is in part mediated by luteal cell apoptosis [70, 71] , and in order to maintain CL viability, activation of apoptosis must be blocked. Bcl-xL, a member of the Bcl-2 protein family, inhibits apoptosis [33] by inhibiting Baxinduced caspase activation and thus blocking the cell death pathway upstream of caspase activity [34] . Also, Bcl-xL promotes cell survival by altering metabolic regulation of acetyl-CoA and N-alpha-acetylation, decreasing sensitivity to proapoptotic stimuli [72] . The serine/threonine kinase AKT, also known as protein kinase B (PKB), is another gene known to have roles in promoting cell survival and growth [35] . Treatment of luteal cells in vitro with PGF suppresses IRS1/ PI3K/AKT signaling, which may manifest as reduced AKT phosphorylation and activity in early luteolysis [73] . Similarly, X-linked inhibitor of apoptosis protein (XIAP), an intracellular antiapoptotic protein that contains a caspase recruitment domain [36] , directly inhibits caspase-3 [37] and caspase-7 [36] and regulates AKT activity in human ovarian epithelial cancer cells [38] . Also, XIAP ubiquitin-protein ligase activity promotes active degradation of caspase-3, but not procaspase-3, in cells [74] . Modulation of XIAP activity may be one mechanism by which IFNT prevents luteolysis, and this is possibly important in light of the importance of caspase-3-dependent apoptosis during luteal regression [75] . Interestingly, CL from roIFNT-infused ewes had increased expression of Bcl-xL, AKT, and XIAP at 24 and 72 h compared to CL from BSA-infused ewes, whereas PGF administration decreased expression of these cell survival genes at 24 h. The results suggest that infusion of roIFNT results in up-regulation of cell survival genes, which are down-regulated during luteolysis, and may be one reason why endocrine actions of IFNT protect against luteolysis and provide luteal resistance during early pregnancy.
The exact amount of IFNT released into the uterine vein and eventually into the systemic circulation during normal maternal recognition of pregnancy period is unknown. For this reason, studies aimed at determining amounts of IFNT released into the uterine vein on Days 12-16 of pregnancy using an IFNT radioimmunoassay and bioassay based on induction of ISG15 mRNA in cultured endometrial cells (BEND cells [76] ) are currently underway. We selected 200 and 20 lg/ml dosages of roIFNT in the present studies based on the results of an antiviral assay indicating the amount of antiviral activity in serum from uterine vein on Day 15 of pregnancy [21, 22] , but these amounts of roIFNT might be greater than what occurs during early pregnancy. In a previous study, we showed that induction of ISG15 protein occurs predominantly in large luteal cells on Day 15 of pregnancy [22] . In the current study, the induction of ISG15 mRNA in roIFNT-treated large luteal cells was similar across the dose range examined. This suggests that these luteal cells are more sensitive to roIFNT and that a lower dose may be sufficient to maintain steroidogenesis and survival.
The ability of roIFNT to block the decline in progesterone concentration induced by injection of 4 mg PGF/48 kg body weight is significant. Whether resistance of the CL to this single pharmacological dose of PGF can be repeated using other models of challenge with PGF remains to be determined. For example, McCracken et al. [77] recently described consistent luteolysis as reflected by decline in serum progesterone concentrations and return to estrus following administration of five 1-h infusions of PGF (20 lg/min/h). Infusion of roIFNT for 24 h prior to infusion of five pulses of PGF might also block or delay luteolysis, but this remains to be determined.
In conclusion, endocrine delivery of roIFNT, regardless of route of administration (uterine or jugular veins) or dose (200 or 20 lg/day), effectively protects the CL against a PGFinduced decline in concentrations of progesterone in serum (luteolysis). Ewes exposed to the concentrations of roIFNT utilized in this study maintained normal body temperature and appeared clinically healthy. The findings of this study corroborate the finding of previous experiments, which demonstrated a significant delay in return to estrus following roIFNT infusion [21] . Luteal resistance to PGF during pregnancy may entail induction of ISGs, down-regulation of luteolytic PTGFR, as well as up-regulation of luteotrophic and immunosuppressive PTGER4 mRNA concentrations identified in this study. Also, cell survival genes, such as Bcl-xL, AKT, and XIAP, may play important roles in sustaining luteal steroidogenesis through preventing apoptosis of luteal cells. The results of the present study provide a base for future approaches aimed at understanding the mechanisms underlying the maternal recognition of pregnancy in ruminants, and increasing pregnancy rates through therapeutic administration of roIFNT to potentially rescue embryos with delayed or deficient IFNT synthesis and/or secretion.
